Eben Tessari Sells 15,091 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock

Key Points

• Eben Tessari, COO of Kiniksa Pharmaceuticals, sold 15,091 shares of the company’s stock at an average price of $35.50, totaling approximately $535,730.50, leading to a 25.34% decrease in his position.
• Kiniksa Pharmaceuticals has recently seen changes in analyst ratings, with Wells Fargo raising its price target from $30.00 to $42.00, while Wall Street Zen downgraded the stock from a "strong-buy" rating to a "buy" rating.
• The company reported earnings of $0.23 per share, surpassing analyst estimates of $0.18, with total revenue during the quarter of $156.80 million, compared to expectations of $145.21 million.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) COO Eben Tessari sold 15,091 shares of the company's stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $35.50, for a total transaction of $535,730.50. Following the transaction, the chief operating officer owned 44,452 shares in the company, valued at $1,578,046. This represents a 25.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Eben Tessari also recently made the following trade(s):

• On Monday, August 18th, Eben Tessari sold 16,200 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $33.77, for a total transaction of $547,074.00.
• On Tuesday, August 5th, Eben Tessari sold 138,614 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $33.20, for a total transaction of $4,601,984.80.
• On Monday, July 14th, Eben Tessari sold 18,900 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $28.72, for a total transaction of $542,808.00.
• On Monday, June 16th, Eben Tessari sold 17,300 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $28.28, for a total transaction of $489,244.00.
• On Wednesday, June 11th, Eben Tessari sold 45,042 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $30.51, for a total transaction of $1,374,231.42.
• On Monday, June 9th, Eben Tessari sold 10,319 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $30.38, for a total transaction of $313,491.22.
• On Tuesday, June 10th, Eben Tessari sold 15,506 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $30.46, for a total transaction of $472,312.76.

Kiniksa Pharmaceuticals International Stock Performance

KNSA traded up $1.20 during trading on Wednesday, reaching $35.48. 600,208 shares of the company traded hands, compared to its average volume of 675,074. Kiniksa Pharmaceuticals International, plc has a 12-month low of $17.82 and a 12-month high of $35.53. The firm has a fifty day simple moving average of $30.51 and a 200 day simple moving average of $26.21. The company has a market cap of $2.63 billion, a P/E ratio of 887.22 and a beta of 0.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, beating analysts' consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The firm had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Several institutional investors and hedge funds have recently added to or reduced their stakes in KNSA. EverSource Wealth Advisors LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 140.4% during the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company's stock worth $25,000 after acquiring an additional 532 shares during the last quarter. Corebridge Financial Inc. grew its stake in shares of Kiniksa Pharmaceuticals International by 3.6% during the first quarter. Corebridge Financial Inc. now owns 15,979 shares of the company's stock worth $355,000 after acquiring an additional 549 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 84.8% during the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after acquiring an additional 568 shares during the last quarter. Sound View Wealth Advisors Group LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 4.0% during the first quarter. Sound View Wealth Advisors Group LLC now owns 14,657 shares of the company's stock worth $326,000 after acquiring an additional 568 shares during the last quarter. Finally, Martingale Asset Management L P grew its stake in shares of Kiniksa Pharmaceuticals International by 1.3% during the first quarter. Martingale Asset Management L P now owns 50,000 shares of the company's stock worth $1,111,000 after acquiring an additional 640 shares during the last quarter. Hedge funds and other institutional investors own 53.95% of the company's stock.

Analyst Ratings Changes

Several analysts recently weighed in on KNSA shares. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a report on Saturday. Wells Fargo & Company lifted their price objective on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a report on Wednesday, July 9th. Jefferies Financial Group lifted their price objective on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a report on Tuesday, July 29th. Finally, Wedbush restated an "outperform" rating and issued a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Six analysts have rated the stock with a Buy rating, According to MarketBeat.com, Kiniksa Pharmaceuticals International currently has an average rating of "Buy" and an average target price of $41.17.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.